TAFAMIDIS MEGLUMINE | FOLDRX PHARMS | ||
20MG | |||
Yes | No | ||
2025-Dec-19 | 2024-May-03 | ||
None | None | ||
None | No | ||
VYNDAQEL is transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. |
0 | 0 | 0 |
Total Other Developers | 6 |
---|
Drugs with Suitability | No |
---|
20MG | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
Yes | 0 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com